Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Human Crossveinless-2/CV-2/BMPER ELISA Kit

Click to view available options
Quantity:
5 x 96 Tests
96 Tests
Description
Human Crossveinless-2/CV-2/BMPER quantitates human Crossveinless-2/CV-2/BMPER in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human Crossveinless-2/CV-2/BMPER.
This gene encodes a secreted protein that interacts with, and inhibits bone morphogenetic protein (BMP) function. It has been shown to inhibit BMP2- and BMP4-dependent osteoblast differentiation and BMP-dependent differentiation of the chondrogenic cells. Mutations in this gene are associated with a lethal skeletal disorder, diaphanospondylodysostosis.

Specifications
Specifications
Accession Number | 3110056H04Rik; BMP binding endothelial regulator; BMP-binding endothelial regulator; BMP-binding endothelial regulator precursor protein; BMP-binding endothelial regulator protein; BMPER; bone morphogenetic protein-binding endothelial cell precursor-derived regulator; Crim3; crossveinless 2; crossveinless-2; Cv2; CV-2; hCV2; KIAA1965; mCV2; Protein crossveinless-2; RGD1563373 |
Assay Range | 0.410 to 100 ng/mL |
Assay Sensitivity | 0.45 ng/mL |
Conjugate | HRP |
Product Type | ELISA |
Sample Type | Plasma, Serum, Supernatant |
For Use With (Equipment) | Colorimetric Microplate Reader |
Gene ID (Entrez) | 168667 |
Gene Symbol | Bmper |
Interassay CV | <12% |
Show More |
Safety and Handling
WARNING: Reproductive Harm - www.P65Warnings.ca.gov
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction